20240208171546.png)
Memorial Sloan-Kettering Cancer Center today launched a transformative initiative to improve the quality of cancer care and the lives of cancer patients. Hartford HealthCare, a multi-hospital health care system in Connecticut, was selected as a pioneering member of the newly formed Memorial Sloan-Kettering Cancer Alliance.
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions.
Memorial Sloan-Kettering Cancer Center has announced the appointment of David R. Jones as Chief of the Thoracic Service in the Department of Surgery, and Charles M. Rudin as Chief of the Thoracic Oncology Service, Division of Solid Tumor Oncology, in the Department of Medicine.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates.
Memorial Sloan-Kettering Cancer Center today unveiled a new pressroom for journalists with enhanced features as well as the availability of an on-site broadcast studio.
A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence. Knowing that this feature exists in a tumor's pathology could be an important factor doctors use to guide cancer treatment decisions.
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to new research from Memorial Sloan-Kettering Cancer Center.
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).
An analysis of endometrial cancers reveals genetic information that should improve diagnosis and guide treatments for women with an aggressive form of the disease.
Scientists from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have collaborated to create a unique monoclonal antibody that can effectively reach inside a cancer cell.
Memorial Sloan-Kettering Cancer Center has announced the appointment of Avice Meehan to Vice President of Communications and Chief Communications Officer.
Memorial Sloan-Kettering Cancer Center announces new appointments.
Charles L. Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program (HOPP), was awarded the Breakthrough Prize in Life Sciences today.
Memorial Sloan-Kettering Cancer Center researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.
IBM (NYSE: IBM), WellPoint, Inc. (NYSE: WLP), and Memorial Sloan-Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.
Memorial Sloan-Kettering Cancer Center has announced the appointment of medical oncologist Paul Sabbatini to the new position of Deputy Physician-in-Chief for Clinical Research.
A new pancreatic cancer research center has been created at Memorial Sloan-Kettering Cancer Center (MSKCC). The ambitious initiative was established with an initial commitment of $10 million from MSKCC Board member David M. Rubenstein.
Memorial Sloan-Kettering Cancer Center announced today that José Baselga has been named Physician-in-Chief of Memorial Hospital.
New data reveals that women treated with radiation to the chest for childhood cancer have a high risk of developing breast cancer similar to that of women with BRCA1/2 mutations.
Researchers from Memorial Sloan-Kettering Cancer Center have begun testing for three new genetic targets and found that together they occur in approximately 50 percent of patients with squamous cell carcinomas of the lung, which affects 40,000 Americans each year. Initial findings of the research will be presented on June 4 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
Women on Long Island who don’t have insurance or who are underinsured may be able to take advantage of free mammograms at Memorial Sloan-Kettering Cancer Center Commack. The Center has contracted with the New York State Cancer Services Program (CSP) of Western Suffolk County to provide breast cancer screening at no cost to patients who are uninsured or underinsured and meet certain eligibility criteria.
Memorial Sloan-Kettering Cancer Center’s website has been nominated for The Webby Award, the most prestigious international award honoring excellence on the Internet.
A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident. There are currently no FDA-approved treatments or prophylactics available to manage the condition, known as radiation gastrointestinal syndrome (RGS), which is associated with weight loss, vomiting, diarrhea, dehydration, systemic infection, and – in extreme cases – septic shock and death.
Memorial Sloan-Kettering Cancer Center and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson in order to provide medical professionals with improved access to current and comprehensive cancer data and practices.
Memorial Sloan-Kettering is the first and only hospital in New York, New Jersey, and Connecticut to offer a new, more patient-friendly approach for doctors to precisely pinpoint and remove very small breast cancers that can be seen on a mammogram but not felt in the breast.
Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan-Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.
A rarely seen phenomenon in cancer patients — in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body — has been reported in a patient with melanoma treated with the immunotherapeutic agent ipilimumab (Yervoy™). Researchers at Memorial Sloan Kettering Cancer Center shared their findings in a unique single-patient study, which could help shed light on the immune system’s role in fighting cancer.
For the first time, a new study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease. Patients in the study were evaluated for up to 23 years after having the procedure, providing the longest follow-up results to date. The collaborative study, led by researchers at Memorial Sloan-Kettering Cancer Center, will be published in the February 23, 2012 issue of The New England Journal of Medicine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right